NCT04674748View on ClinicalTrials.gov

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

May 13, 2022

Study Completion Date

May 13, 2022

Conditions
Solid Tumors
Interventions
DRUG

INCB086550

Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.

Trial Locations (2)

277-8577

National Cancer Center Hospital - East, Chiba

104-0045

National Cancer Center Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Incyte Biosciences Japan GK

INDUSTRY

NCT04674748 - To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 | Biotech Hunter | Biotech Hunter